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In Europe, advanced therapy medicinal products
(ATMPs), including cell and gene medicinal prod-
ucts [1], tissue-engineered products [2] and com-
bined ATMPs [2], are governed by Directive 2001/
83/EC [3] and Regulation 726/2004 [4], amended by
Regulation 1394/2007 [2], which sets speciﬁc rules
concerning their centralized marketing authorization
(MA), supervision and pharmacovigilance.
Nevertheless, ATMPs not intended to be marketed
and not industrially prepared are beyond the scope of
Directive 2001/83/EC, according to article 28 of
Regulation 1394/2007. This is commonly called “hos-
pital exemption” (HE) and is restricted to any ATMP
“which is prepared on a non-routine basis according to
speciﬁc quality standards, and used within the same
Member State in a hospital under the exclusive profes-
sional responsibility of amedical practitioner, inorder to
comply with an individual medical prescription for a
custom-made product for an individual patient.”
Member States must ensure that the manufacture of
ATMPs under HE is authorized by the competent na-
tional authority and that traceability, pharmacovigilance
and speciﬁc quality standards are equivalent to those
applying to ATMPs granted centralized MA.
HE requires transposition into national laws.
Some European countries have already done this,
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pretation of HE has led them to setting sometimes-
divergent pathways and rules [5].Primary issue arising within the scope of HE
Directive 2001/83/EC does not specify what is meant
by “industrial process,” nor does the regulation
specify the meaning of a “custom-made product.”
Nevertheless, some countries have deﬁned those
terms. In the United Kingdom, the Human Tissue
Authority [6] has deﬁned “custom-made” as “using a
one-off formulation or a formulation that has been
tailored to the individual patient and prepared within
the same hospital” and “An industrial process would
generally take place in an external facility and not
within the same hospital.” This is a speciﬁc inter-
pretation; the process (industrial or not) is the most
important aspect, not the location, because the same
process can take place in facilities inside or outside
hospitals. In fact, HE clause (Regulation 1394/2007)
is in effect irrespective of the type of manufacturer.Different interpretation of HE in European
Countries
Countries have interpreted the deﬁnition of “non-
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number to constitute “non-routine.” The United
Kingdom takes the view that “it is not feasible to
provide a simple numerical formula that would
delineate the boundary between routine and non-
routine production” [7]. The Netherlands has cho-
sen a concrete deﬁnition of “non-routine basis,”
allowing the infusion of one product for a maximum
of ﬁve patients and fewer than ten patients a year [8].
The German Medicinal Products Act [9] has deﬁned
ATMPs prepared on a non-routine basis as those
“medicines which are manufactured in small quan-
tities, and in the case of which, based on a routine
manufacturing procedure, variations in the proce-
dure which are medically justiﬁed for an individual
patient, are carried out, or which have not yet been
manufactured in sufﬁcient quantities so that the
necessary data to enable a comprehensive assessment
are not yet available.” In the case of Finland [10,11]
France [12], Spain [13] and Portugal [14], there are
no provisions for any speciﬁc quantity.
Regarding the entity holding the license, most
countries grant HE to ATMP manufacturers, and in
Spain and Portugal the license is given to hospitals. In
Spain the licence is irrespective of the manufacturer.
Therefore, if several Spanish hospitals were interested
in using anATMPproduced by a singlemanufacturer,
each hospital should submit a dossier equivalent to a
Common Technical Document.
Although most countries require Good
Manufacturing Practice (GMP) as the quality stan-
dard applicable under the HE scheme, there are
some differences. In the United Kingdom, a quali-
ﬁed person is not required [15]. In Germany, “per-
son identity” of the manufacturer is not necessary.
Although GMP is required in the Netherlands,
France and Spain, there is some degree of ﬂexibility.When does HE apply?
Perhaps the most important issue regarding HE is
the situation or circumstances in which it applies
with marked differences among countries. In the
United Kingdom, the HE scheme “does not apply to
ATMPs that will be authorised under the ATMP
Regulation . nor does it apply to ATMPs supplied
as investigational ATMPs for use in a clinical trial
(CT) [15].” Nevertheless, the United Kingdom
established a second scheme for unlicensed products
by implementing a procedure to supply “specials”
(ATMPs) under Article 5(1) of Directive 2001/83/
EC that, in contrast to HE, allows import and export
of unlicensed ATMPs. The Netherlands applies HE
for patients ineligible for a CT (as in compassionate
use) or when the required product falls outside thespeciﬁcations. In Finland, quality (but not non-
clinical) data are required, allowing small-scale
clinical use while non-clinical studies are carried out
to facilitate a later CT. However, in Spain it is only
possible to apply for HE when efﬁcacy and safety
have been demonstrated, and quality, non-clinical
and clinical data must be provided. Here HE
is considered as an alternative to MA for products
non-industrially manufactured and not intended to
be marketed, but not as an alternative to CTs. In
Germany HE may be applicable to facilitate or
accompany a CT (not as an alternative) but also for
conveying products in a preliminary “non-routine
status” on their way to centralized MA. In France,
ATMP under HE require same clinical trials than
other medicinal products and in Portugal there are
no provisions regarding when HE applies.
On the subject of the duration of the authoriza-
tion under HE, in Netherlands the product-speciﬁc
license lasts for 10 batches or for 1 year, whereas in
Germany there is no precise product-speciﬁc license
period. In the case of Finland, the license for non-
industrial manufacture of ATMPs may be granted
for a ﬁxed or indeﬁnite term, in Portugal is granted
by one year being renewable and in Spain authori-
zation is initially granted for 3 years and then for 5
years in successive renewals.The concerns of the affected stakeholders
Small and medium enterprises and non-for-proﬁt or-
ganizations (mainly universities and public hospitals)
are leading the clinical development of ATMPs in
Europe, with great variability among countries. In
Spain and Italy the role of industry has been minimal,
whereas in the United Kingdom, Germany, France,
Sweden and Denmark, it has been quite important
[16]. These differences have probably been instru-
mental in the way National Authorities have imple-
mentedHE.Here there are several examples.Germany
has been the leading country in granting products un-
derHE,most of them in theGermanmarket before the
entry into force of the Regulation 1394/2007/EC. This
has allowed those companies that have not applied for
or have not been granted a European MA to continue
their activity there. Although the United Kingdom was
one of the ﬁrst countries regulatingHE, the majority of
the authorizations to manufacture and supply unli-
censed ATMPs have been granted under the United
Kingdom’s “Specials” scheme. This scheme permits
import and export activities, affording competitive
advantage for the United Kingdom in comparison to
other countries. Spain, with unlicensed ATMPs
included in the Common Services Portfolio of the
NationalHealthcareSystemas standardof carewithout
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an authorization for hospital use, but not as a national
MA. This might maintain the provision of those treat-
ments in hospitals.
Because of these differences between countries,
members from both industry and academia are
demanding harmonization in HE rules [17]. In the
case of industry, regulatory predictability is important
in making large investments, as is market size and
market access unhindered by unfair competition [18].
However, HE was provided to allow some ﬂexibility
and to enable Member States to ﬁt their individual
circumstances to ATMPRegulation, as we have seen.
The recent report onATMPsRegulation published
by the European Commission [19] states: “It is neces-
sary to ﬁnd a balance between the need to ensure that
ATMPs are made available to patients only after the
quality, efﬁcacy and safety thereof has been adequately
demonstrated, and the need to facilitate early access for
new treatments in case of unmet medical needs.”
In this sense, some developers are concerned
about the availability of ATMPs that were part of
established clinical practice before the introduction
of ATMP regulation as well as upcoming products
with documented clinical efﬁcacy that are currently
not candidates for MA because of insufﬁcient pre-
clinical data. For these products, the current HE may
be too restrictive in some cases.
There are also other situations that do not ﬁt
perfectly into the current regulation, especially for
those products with little commercial interest but that
are addressing unmet clinical needs. Where products
lack intellectual property (especially minimally
manipulated autologous products derived from pro-
cessing technologies broadly used inmost hospitals for
other similar products not considered as ATMPs, i.e.,
bonemarrow cells) [20], it could be useful to facilitate
their introduction into practice irrespective of the
number of patients treated once their quality is guar-
anteed and safety and efﬁcacy have been demon-
strated in randomized clinical trials [21]. For other
products in which low disease prevalence discourages
enterprises because of the small potential market, and
orphan designation may not be suitable, HE should
allow import and export activities.
The latter situationsmainly concern institutionswith
a primary focus in generating knowledge and enabling
patient access to safe and efﬁcacious noneindustrially
manufactured ATMPs with reduced interest in mar-
keting those products. The modiﬁcation of the regula-
tion and potential broadening of the HE limits
speciﬁcally in products with reduced commercial po-
tential while supporting the granting of MA for indus-
trially prepared products intended to bemarketed could
thus beneﬁt all stakeholders, allowing European publichealthcare systemsandacademicGMPs tocomplement
rather than competewith small andmediumenterprises.References
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